Idexx Laboratories (IX1) Stock Statistics & Valuation Metrics
Total Valuation
Idexx Laboratories has a market cap or net worth of EUR 38.75B. The enterprise value is EUR 42.65B.
- Market Cap
- EUR 38.75B
- Enterprise Value
- EUR 42.65B
Share Statistics
Idexx Laboratories has 78,781,110 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 78,781,110
- Owned by Insiders
- 0.23%
- Owned by Institutions
- 65.34%
Financial Efficiency
Idexx Laboratories’s return on equity (ROE) is 0.66 and return on invested capital (ROIC) is 40.27%.
- Return on Equity (ROE)
- 0.66
- Return on Assets (ROA)
- 0.32
- Return on Invested Capital (ROIC)
- 40.27%
- Return on Capital Employed (ROCE)
- 0.62
- Revenue Per Employee
- 391.25K
- Profits Per Employee
- 96.31K
- Employee Count
- 11,000
- Asset Turnover
- 1.28
- Inventory Turnover
- 4.35
Valuation Ratios
The current PE Ratio of Idexx Laboratories is 38.71. Idexx Laboratories’s PEG ratio is 2.19.
- PE Ratio
- 38.71
- PS Ratio
- 9.54
- PB Ratio
- 27.38
- Price to FCF
- 34.72
- Price to Operating Cash Flow
- 32.28
- PEG Ratio
- 2.19
Income Statement
In the last 12 months, Idexx Laboratories had revenue of 4.30B and earned 1.06B in profits. Earnings per share was 13.17.
- Revenue
- 4.30B
- Gross Profit
- 2.66B
- Operating Income
- 1.36B
- Pretax Income
- 1.32B
- Net Income
- 1.06B
- EBITDA
- 1.51B
- Earnings Per Share (EPS)
- 13.17
Cash Flow
In the last 12 months, operating cash flow was 1.37B and capital expenditures -117.18M, giving a free cash flow of 1.25B billion.
- Operating Cash Flow
- 1.37B
- Free Cash Flow
- 1.25B
- Free Cash Flow per Share
- 15.61
Dividends & Yields
Idexx Laboratories pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 2.88%
- Earnings Yield
- 2.58%
Stock Price Statistics
- Beta
- 0.72
- 52-Week Price Change
- -10.41%
- 50-Day Moving Average
- 468.22
- 200-Day Moving Average
- 492.41
- Relative Strength Index (RSI)
- 52.75
- Average Volume (3m)
- 14
Important Dates
Idexx Laboratories upcoming earnings date is Nov 02, 2026, Before Open (Not Confirmed).
- Last Earnings Date
- Aug 04, 2026
- Next Earnings Date
- Nov 02, 2026
- Ex-Dividend Date
- ―
Financial Position
Idexx Laboratories as a current ratio of 1.17, with Debt / Equity ratio of 67.10%
- Current Ratio
- 1.17
- Quick Ratio
- 0.84
- Debt to Market Cap
- 0.02
- Net Debt to EBITDA
- 0.60
- Interest Coverage Ratio
- 35.54
Taxes
In the past 12 months, Idexx Laboratories has paid 264.73M in taxes.
- Income Tax
- 264.73M
- Effective Tax Rate
- 0.20
Enterprise Valuation
Idexx Laboratories EV to EBITDA ratio is 27.40, with an EV/FCF ratio of 35.44.
- EV to Sales
- 9.73
- EV to EBITDA
- 27.40
- EV to Free Cash Flow
- 35.44
- EV to Operating Cash Flow
- 32.41
Balance Sheet
Idexx Laboratories has EUR 196.93M in cash and marketable securities with EUR 1.10B in debt, giving a net cash position of -EUR 899.15M billion.
- Cash & Marketable Securities
- EUR 196.93M
- Total Debt
- EUR 1.10B
- Net Cash
- -EUR 899.15M
- Net Cash Per Share
- -EUR 11.41
- Tangible Book Value Per Share
- EUR 13.78
Margins
Gross margin is 62.45%, with operating margin of 32.03%, and net profit margin of 25.03%.
- Gross Margin
- 62.45%
- Operating Margin
- 32.03%
- Pretax Margin
- 31.28%
- Net Profit Margin
- 25.03%
- EBITDA Margin
- 35.53%
- EBIT Margin
- 32.14%
Analyst Forecast
The average price target for Idexx Laboratories is EUR 631.30, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- EUR 631.30
- Price Target Upside
- 29.10% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 10
- Revenue Growth Forecast
- 5.23%
- EPS Growth Forecast
- 10.48%
Scores
- Smart Score
- 6
- AI Score
- ―